|GenoMed's WNV Treatment Abruptly Stopped, Patient Deteriorates|
Contact: David W. Moskowitz MD FACP GenoMed, Inc. Tel. 314.983.9933
PHILADELPHIA, PA.--June 24, 2005--GenoMed (the "Company") (Pink Sheets GMED), a Next Generation DM(tm) company that uses molecular medicine to improve patient outcomes and save healthcare costs, announced today that its first presumed West Nile virus encephalitis patient is doing poorly after GenoMed's treatment was abruptly stopped last week.
The patient received two doses of GenoMed's treatment for WNV on Wednesday and early Thursday morning last week, and appeared to get better according to her mother (see 6/16/05 press release). When she was moved to the Intensive Care Unit for closer monitoring, her new Attending Physician could not be convinced of the usefulness of GenoMed's treatment, and stopped it. She has been without GenoMed's treatment for over a week now.
Said Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, "I happened to be in Philadelphia this week for a Disease Management conference, and visited the patient in the ICU on Wednesday evening. She had evidence of decorticate posturing then, constantly shrugging her shoulders inwards. She was unresponsive to pain or verbal stimuli. The situation looked grim."
Added Dr. Moskowitz, "We will never know in this poor patient's case what would have happened if she had just stayed on our treatment. Perhaps she would be exactly as sick as she is now. But it looked like she was getting better, as eleven out of fourteen of our patients have done the past two summers. Now she has full-blown viral encephalitis, and the eventual outcome does not look good. "
The patient's initial serum test for West Nile virus was negative, as is usually the case, so she has not yet been reported to the health authorities. A convalescent serum titer will be drawn in several weeks to see if she has WNV.
GenoMed is a Next Generation DM(tm) [Disease Management] company that uses molecular medicine to improve patient outcomes and thus lower healthcare costs. Although the Company has effective treatments, there are obstacles to their adoption, as illustrated by this example. Currently, the company is marketing its protocols for preventing kidney failure from diabetes and high blood pressure, and significantly delaying emphysema.
GenoMed is conducting a free trial for WNV for the third consecutive summer. Those interested in participating are invited to download the trial documents from the Company's home page at www.genomed.com